Hims & Hers sees ‘an exciting period of growth,’ but stock falls - MarketWatch
1. Hims & Hers' Q3 revenue forecast fell short, impacting after-hours shares. 2. Company maintains full-year sales outlook despite disappointing quarterly earnings forecast. 3. CEO stresses growth in high-impact specialties, expanding personalized care offerings. 4. Company faces backlash from Novo Nordisk over promotion and product legitimacy. 5. Stock up 161.9% YTD, yet shares dropped 11.8% in after-hours trading.